Bristol-Myers Squibb

Senior Quality Training Specialist

Indianapolis, Indiana, United States

$60,000 – $90,000Compensation
Mid-level (3 to 4 years), Junior (1 to 2 years)Experience Level
Full TimeJob Type
UnknownVisa
Pharmaceutical, Quality AssuranceIndustries

Requirements

Candidates should possess a Bachelor’s degree in a relevant scientific field, such as Biology, Chemistry, or Pharmaceutical Sciences, and have at least five years of experience in quality assurance or training within a pharmaceutical or biotechnology environment. Strong understanding of quality systems, regulatory requirements (including FDA and GMP guidelines), and training methodologies is essential. Experience with electronic Quality Management Systems (eQMS) is highly desirable.

Responsibilities

The Senior Quality Training Specialist will assist with the implementation of the RayzeBio Training Management program, setup new users in the eQMS, maintain training matrices, assign training courses, organize instructor-led training courses, update eQMS users, inactivate users upon departure, and ensure documented training evidence. They will also participate in establishing training best practices, working with Human Resources to ensure personnel maintain updated job roles and responsibilities, and serve as a subject matter expert in management related to quality systems.

Skills

GMP
FDA
Quality Systems
Training Methodologies
eQMS
Regulatory Requirements
Documentation
Auditing

Bristol-Myers Squibb

Develops and delivers biopharmaceutical medicines

About Bristol-Myers Squibb

Bristol Myers Squibb (BMS) develops and delivers medicines aimed at treating serious diseases, focusing on areas like cancer, autoimmune diseases, and heart conditions. The company conducts extensive research and development to create new drugs, which are sold after receiving regulatory approval. BMS also produces generic drugs, offering affordable alternatives that meet the same quality standards as their branded counterparts. What sets BMS apart from competitors is its dual focus on both innovative and generic medicines, enhancing access to healthcare. The company's goal is to improve patient outcomes while maintaining a commitment to sustainability and corporate responsibility.

Key Metrics

New York City, New YorkHeadquarters
1887Year Founded
$33,706.1MTotal Funding
IPOCompany Stage
Biotechnology, HealthcareIndustries
10,001+Employees

Benefits

Flexible Work Hours
Hybrid Work Options
Professional Development Budget

Risks

Increased competition in oncology from emerging biotech firms like ArsenalBio.
BMS's lawsuit over the 340B Drug Pricing Program may lead to regulatory challenges.
Rapid AI and digital tech evolution may pose integration challenges for BMS.

Differentiation

BMS focuses on innovative cancer treatments through collaborations like ArsenalBio for T cell therapies.
The company emphasizes digital health technologies, enhancing clinical trial management and patient engagement.
BMS offers both innovative and generic medicines, increasing affordable healthcare solutions.

Upsides

BMS's partnership with Medidata enhances clinical research processes and patient outcomes.
The collaboration with AI Proteins advances novel miniprotein-based therapeutics, expanding therapeutic modalities.
BMS's global license agreement with BioArctic expands its portfolio in neurodegenerative diseases.

Land your dream remote job 3x faster with AI